Pancreatic Cancer is the fourth leading cause of cancer related deaths in the US. Approximately, 338,000 new cases of pancreatic cancer are estimated worldwide with ~ 46,420 cases expected in the US in 2014. Treatments include surgery, radiation and chemotherapy. Surgery is usually performed in ~ 20% of the newly diagnosed patients, mostly in conjunction with radiation and adjuvant chemotherapy. Approved drugs include Tarceva, Abraxane and the most widely used chemotherapeutic drug, Gemcitabine, a nucleoside analog that affects DNA replication resulting in cell apoptosis. ES-4000 has demonstrated promise in the treatment of pancreatic cancer by targeting the over expression of c-Myc. Recent studies have shown that increased c-Myc expression in pancreatic cancer correlates with poor prognosis and tumor progression. In cell culture and xenograft models, down regulation of c-Myc has been correlated to increased apoptosis and tumor regression. Our product, ES-4000 strongly down regulates the expression of c-Myc. It is active at low nM concentrations and more active than taxanes and camptothecins, both in vitro and in vivo. It has been demonstrated that c-Myc is over expressed in hematologic and solid malignancies, particularly in pancreatic cancer. ES-4000 was found active in phase I clinical studies with heavily pretreated patients for metastatic breast cancer and melanoma. ES-4000 targets c‑Myc expression for which no therapeutic has yet been developed. Therefore, inhibition of c-Myc over expression by ES-4000 can be exploited as a novel therapy for pancreatic cancer.